Jun 27 |
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
|
Jun 13 |
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
|
May 25 |
Nkarta: Finally An Attractive Valuation
|
May 23 |
Nkarta: A Look Into Q1 Results And Upcoming Catalysts
|
May 11 |
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
|
May 10 |
Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis
|
May 9 |
Nkarta GAAP EPS of -$0.58 misses by $0.02
|
May 9 |
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
|
May 7 |
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street’s Radar
|
Apr 27 |
Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
|